PEA (palmitoylethanolamide): endocannabinoid-like compound for pain (table)
PEA (palmitoylethanolamide) in chronic pain: how many people were studied, what two meta-analyses from Pain Physician say, and what is unknown about the micronized form.
Palmitoylethanolamide (PEA) is a lipid that the body produces in inflamed or damaged tissue. It has been present in supplements for several years, usually with the promise of pain relief without the gastrointestinal side effects of anti-inflammatory drugs. There is evidence supporting its use, and it is more substantial than that for a typical supplement, but narrower than product descriptions suggest. It consists of two meta-analyses published in Pain Physician, several clinical trials, and one large registration study on sciatica. However, some of these are open-label studies without a control group, and one of the meta-analyses was co-authored by employees of the manufacturer. This article separates what has been measured in humans from what has been measured in cell cultures and rodents, and shows where the evidence falls short and what questions are worth asking before making a purchase.
KEY INFORMATION
• PEA is an endogenous N-acylethanolamine; it primarily acts through the nuclear receptor PPAR-alpha, not through the CB1 and CB2 receptors.
• Two meta-analyses in Pain Physician evaluated PEA in chronic pain: a pool of 12 studies (Paladini, Pain Physician, 2016) and 10 studies involving 786 individuals taking PEA compared to 512 individuals in control groups (Artukoglu, Pain Physician, 2017).
• The largest single trial is a registration study on low back pain with sciatica: 636 patients, three weeks, arms of 300 and 600 mg per day versus placebo (Cruccu, CNS Neurol Disord Drug Targets, 2019).
• The superiority of the micronized form over the regular form has not been demonstrated: a review in the British Journal of Clinical Pharmacology states that there are no studies directly comparing both forms (Gabrielsson, Br J Clin Pharmacol, 2016).
• The 2016 meta-analysis was co-authored by employees of the micronized PEA manufacturer, which the reader should be aware of when assessing its significance.
What is PEA and why is it sometimes referred to as an endocannabinoid-like compound?
PEA belongs to the family of N-acylethanolamines (NAE), the same as anandamide, the first known endocannabinoid. The relationship is chemical, not functional: PEA does not significantly bind to CB1 or CB2 receptors. The term "endocannabinoid-like" thus refers to the molecular structure and shared degrading enzymes, not to a common receptor.
The main described molecular target of PEA is the nuclear receptor PPAR-alpha. A receptor review dedicated to both of these lipids mentions alongside it the TRPV1 channel and the membrane receptors GPR119 and GPR55, noting that the affinity for individual proteins varies and is not well measured everywhere (Im, Int J Mol Sci, 2021). At the tissue level, the described mechanism is the inhibition of mast cell degranulation and the dampening of glial activation.
It is worth immediately noting the limits of this description. The cellular mechanism comes from cultures and animal models, not from measurements in patients. A study describing an enzyme inhibitor that breaks down PEA showed a reduction in pain sensitivity in mice and rats after topical application, and the effect disappeared in animals lacking PPAR-alpha (Sasso, Pain, 2013). This is strong evidence for the pathway, but not proof that a capsule works the same way in humans.
Does PEA actually reduce pain?
The answer is: in studies on chronic pain, PEA performs better than control, but the quality of these studies is uneven, and the two meta-analyses counted different things. The pool from 2016 included twelve studies, but only three of them had a double-blind trial and placebo; two were openly compared to standard therapy, and seven had no reference group at all.
| Work | Who was included | What was compared | Result reported by the authors |
|---|---|---|---|
| Paladini, Pain Physician, 2016 | a pool of 12 studies, including 3 with placebo | PEA mikronizowany i ultramikronizowany wobec kontroli | a pain reduction of 1.04 points over 2 weeks compared to 0.20 in the control; on day 60, a pain score of 3 or lower in 81% compared to 40.9% |
| Artukoglu, Pain Physician, 2017 | 10 studies, 786 individuals on PEA and 512 in control | only randomized trials, 8 of them in the meta-analysis | a difference of 2.03 points on the VAS scale, confidence interval 1.19-2.87 |
| Cruccu, CNS Neurol Disord Drug Targets, 2019 | 636 patients with low back pain and sciatica | 300 and 600 mg per day versus placebo, 3 weeks | NNT 1.7 for pain and 1.5 for function; the effect increased with the likelihood of a neuropathic component |
| Schifilliti, Pain Res Treat, 2014 | 30 individuals with diabetic neuropathy | 300 mg dwa razy dziennie, ocena po 30 i 60 dniach | significant reduction in pain severity across three symptom scales, without a control group |
A difference of 2.03 points on the VAS scale is significant and clinically noticeable, but the authors themselves qualified it with a caveat: there were few studies, they concerned different causes of pain, had different designs, and the reporting of adverse effects was rated as poor. The 2016 meta-analysis was co-authored by employees of Epitech Group, the manufacturer of micronized PEA, which is evident in the affiliations of two authors.
Does the micronized form absorb better than the regular one?
It's unclear, as no one has directly compared them. This is a conclusion that most diverges from what the labels promise. A pharmacokinetic review in British Journal of Clinical Pharmacology analyzed the available literature and stated outright that there are no studies comparing the non-micronized form with the micronized one head-to-head, therefore evidence for the superiority of either currently does not exist (Gabrielsson, Br J Clin Pharmacol, 2016).
This does not mean that particle size is insignificant. It means that the argument for the higher bioavailability of the ultramicronized form is currently a theoretical argument, based on the physicochemical properties of the powder, rather than a comparative measurement of concentrations in humans. The same review notes that published trials lacked basic information on the spread of results and on measurements at intermediate points, making any comparison of forms between studies difficult.
The practical conclusion for the reader is cautious. If a manufacturer claims that their product is effective at a lower concentration of the substance because it is ultramicronized, this is a marketing claim, not a reading from a comparative study. It is worth asking about this and requesting a reference to a study where both forms were compared.
W jakich wskazaniach PEA badano u ludzi?
The best-documented area is lower back pain with a radicular component. A registration study from 2010 included 636 patients in a multicenter design, with a double-blind trial and three arms, lasting three weeks. A re-analysis of this data showed that the higher the probability of neuropathic pain in the patient, the better the treatment effect, although this correlation did not pertain to improvement in function (Cruccu, CNS Neurol Disord Drug Targets, 2019). The distinction between nociceptive and neuropathic pain is discussed more extensively in our post about the two types of pain and their different responses to cannabinoids..
In diabetic neuropathy, an open-label study was published involving 30 patients who were administered 300 mg twice daily, with assessments at 30 and 60 days. Improvement in three symptom scales was statistically significant, but the design lacked a control group or blinding, so the placebo effect remains indistinguishable from the action of the product (Schifilliti, Pain Res Treat, 2014).
In pelvic pain due to endometriosis, a randomized trial with placebo was conducted on 61 women after laparoscopic surgery. The patients received not just PEA, but a combination with transpolidatin, and the result was better than placebo. However, the same study notes that celecoxib reduced pelvic pain more effectively than the combination tested (Cobellis, Eur J Obstet Gynecol Reprod Biol, 2011). Reports on arthritis, irritable bowel syndrome, and multiple sclerosis come from animal models and cell cultures, so they should not be read as indications.
How does PEA differ from CBD?
They differ in origin and receptor target, and primarily in the type of evidence we have. PEA is produced in human cells and mainly acts through the nuclear receptor PPAR-alpha. CBD comes from the plant and has been described over the years as an inhibitor of the enzyme FAAH, which breaks down anandamide. This description now requires correction: a study in Journal of Biological Chemistry showed that CBD does not inhibit human FAAH, but only the rodent enzyme, and proposed a different mechanism for increasing anandamide in humans, namely competition for intracellular transport proteins from the FABP family (Elmes, J Biol Chem, 2015).
The second difference concerns how far the safety assessment extends. For CBD, there is a current official opinion: the EFSA panel derived a provisional safe dose of 0.0275 mg per kilogram of body weight per day, which is about 2 mg daily for a person weighing 70 kg, and noted that safety cannot be established in individuals under 25 years of age, in pregnant and breastfeeding women, and in people taking medications (EFSA, EFSA Journal, 2026). There is no analogous document for PEA.
The third difference is the area of clinical evidence. PEA has been primarily studied in chronic pain; CBD has the strongest data in drug-resistant epilepsy. No comparisons of both compounds in the same patient have been conducted in any published randomized trial, so claims of synergy remain hypothetical. We discuss the family of these lipids more broadly in our post about the expanded endocannabinoid system..
What is known about the safety of PEA?
The authors of a 2016 meta-analysis noted that none of the studies included reported serious adverse events related to PEA. However, the observation period is short, and this caveat is more important than the mere absence of a signal. The 2016 review states that for treatments lasting up to 49 days, the data argue against the occurrence of serious reactions at a frequency of one in two hundred or greater. For treatments exceeding 60 days, however, the number of subjects studied is too small to exclude a frequency of one in a hundred (Gabrielsson, Br J Clin Pharmacol, 2016).
The number that circulates in product descriptions is "six thousand patients without serious events." It has its source: a review of nerve compression syndromes states that since the 1970s, PEA has been evaluated in over thirty clinical trials involving a total of about 6000 people, and in nerve compression syndromes alone, eight studies have been published on 1366 patients (Keppel Hesselink, J Pain Res, 2015). However, this number describes the total of participants in efficacy studies, not a prospective safety registry, and should not be read as evidence of long-term safety.
Little is known about drug interactions with PEA, and the absence of reports is not the same as demonstrated lack of interactions. If pain is chronic and being treated, the decision to add the product should be made with the attending physician, especially when simultaneously taking painkillers or anticonvulsants. Separately, regarding what is known about cannabis in the same indication, we write in our post about trigeminal neuralgia.
Frequently Asked Questions
Does PEA work for neuropathic pain?
In studies on chronic pain, PEA performs better than control. A meta-analysis involving 10 randomized trials, 786 people on PEA and 512 in control groups, showed a difference of 2.03 points on the VAS scale with a confidence interval from 1.19 to 2.87 (Artukoglu, Pain Physician, 2017).
How many people were studied in total in trials on PEA?
A review of nerve compression syndromes states that since the 1970s, the compound has been evaluated in over thirty clinical trials involving about 6000 people. The largest single trial is a registration study in sciatica with 636 patients, lasting three weeks.
Is the ultramicronized form better than the regular one?
This has not been demonstrated. The pharmacokinetic review states that there are no studies directly comparing the non-micronized form with the micronized one, so the superiority of either remains unproven (Gabrielsson, Br J Clin Pharmacol, 2016). The argument for higher bioavailability is currently theoretical.
How does PEA differ from CBD?
PEA is produced by the body and mainly acts through the nuclear receptor PPAR-alpha. CBD comes from the plant, does not inhibit human FAAH, and raises anandamide levels through a different pathway, by competing for FABP transport proteins (Elmes, J Biol Chem, 2015).
Does PEA have known side effects?
For treatments lasting up to 49 days, the data suggests a low incidence of severe reactions at a rate of one in two hundred or greater. Beyond 60 days, the number of participants is too small to rule out a frequency of one in a hundred. There is little known about drug interactions, so it is advisable to discuss the decision with a doctor.
This article is for informational and educational purposes and does not constitute medical advice. Before starting supplementation, consult your doctor, especially if you are taking medications regularly, are pregnant or breastfeeding, or have a chronic illness.
Author: Michał Waluk · Opublikowano: 2026-07-15 · Aktualizacja: 2026-08-16
